Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Prostate Cancer Prostatic Dis 2019 09 14;22(3):420-427. Epub 2019 Jan 14.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Background: In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer therapies on the OS of patients with mCRPC.

Methods: Two cohorts of patients diagnosed with mCRPC between 2004 and 2007, treated with drugs used in the limited treatment era only (A), and between 2010 and 2013, treated also with newer therapies (B), were identified from the Dana-Farber Cancer Institute database. The analysis endpoint was OS within 5 years after mCRPC diagnosis. Kaplan-Meier method assessed time-to-event distributions with median (95% confidence interval (CI)). A piece-wise regression model assessed the association between endpoint and treatment cohorts with estimate of hazard ratio (HR) with 95% CI within two time segments in univariate and multivariable analyses adjusting for relevant covariates.

Results: Compared to cohort A (n = 318), cohort B (n = 272) patients in newer therapy era demonstrated an OS advantage (2.8 vs. 2.2 years) with a 41% decreased risk of death (HR = 0.59; 95% CI, 0.47-0.74; P < 0.0001), and a 3-year OS rate of 46% vs. 33%. This benefit was accentuated (median OS 2.7 vs. 2.1 years; HR = 0.46; 95% CI, 0.32-0.67; P < 0.0001) in patients who initially presented with de-novo metastatic disease (de-novo). On multivariable analysis, longer OS was associated with cohort B vs. A and performance status 0 vs. 1.

Conclusions: Using a single-institution registry, mCRPC patients treated since 2010 had a significant survival improvement vs. those treated before 2010. Although the median survival was only modestly improved and less than predicted when simply adding each newer drug survival advantage, the cumulative benefit from the new therapies was more pronounced in longer-term survivors and de-novo patients.

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0121-2
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0121-2DOI Listing
September 2019
31 Reads

Publication Analysis

Top Keywords

patients metastatic
8
survival patients
8
newer therapies
8
systemic therapies
8
prostate cancer
8
patients
5
median 95%
4
distributions median
4
time-to-event distributions
4
method assessed
4
assessed time-to-event
4
95% confidence
4
piece-wise regression
4
assessed association
4
association endpoint
4
endpoint treatment
4
model assessed
4
regression model
4
interval piece-wise
4
kaplan-meier method
4

References

(Supplied by CrossRef)

HI Scher et al.
PLoS One 2015

IF Tannock et al.
N Eng J Med 2004

DP Petrylak et al.
N Engl J Med 2004

PW Kantoff et al.
N Engl J Med 2010

JS Bono de et al.
Lancet 2010

JS Bono de et al.
N Engl J Med 2011

CJ Ryan et al.
N Engl J Med 2013

HI Scher et al.
N Engl J Med 2012

TM Beer et al.
N Engl J Med 2014

C Parker et al.
N Engl J Med 2013

Similar Publications